pneumonia
sixth
lead
caus
death
unit
state
number
one
caus
death
infecti
diseas
patient
pneumonia
manag
intens
care
unit
icu
sever
form
communityacquir
pneumonia
cap
present
hospit
patient
develop
lifethreaten
nosocomi
pneumonia
np
newli
defi
ned
entiti
health
careassoci
pneumonia
hcap
form
np
aris
patient
contact
environ
nurs
home
hemodialysi
center
expos
multidrugresist
bacteria
present
hospit
patient
frequent
develop
sever
pneumonia
icu
almost
episod
np
occur
patient
mechan
ventil
reason
term
ventilatorassoci
pneumonia
vap
elderli
account
disproportion
number
critic
ill
patient
form
pneumonia
often
commonli
comorbid
ill
predispos
sever
form
infect
shortand
longterm
mortal
higher
younger
patient
form
sever
pneumonia
antibiot
resist
increas
problem
especi
among
pneumococci
cap
pseudomona
aeruginosa
acinetobact
spp
extendedspectrum
gramneg
methicillinresist
staphylococcu
aureu
mrsa
vap
hcap
although
patient
hiv
infect
immunocompromis
diseas
commonli
develop
pneumonia
approach
manag
patient
specifi
c
differ
use
immunocompet
patient
therefor
popul
discuss
pneumonia
unusu
among
medic
ill
pathogenesi
therapi
prevent
discuss
tremend
controversi
best
diagnos
presenc
although
clinic
defi
nition
requir
presenc
new
radiograph
infi
ltrate
support
clinic
inform
presenc
infect
diagnosi
ventilatorassoci
pneumonia
imprecis
physician
releg
manag
patient
imperfect
perspect
consider
controversi
exist
whether
precis
accur
bacteriolog
defi
nition
pneumonia
would
lead
improv
patient
outcom
recent
studi
focus
issu
numer
controversi
relat
pneumonia
therapi
prevent
also
debat
among
critic
care
physician
discuss
chapter
destabil
anoth
seriou
medic
problem
patient
sever
cap
expect
mortal
rate
admit
icu
higher
rate
observ
major
icuadmit
patient
mechan
ventil
impli
prognosi
wors
icu
care
fi
rst
provid
late
cours
ill
one
recent
studi
found
cap
account
icu
admiss
unit
kingdom
admit
within
fi
rst
day
hospit
stay
group
mechan
ventil
icu
entri
mortal
rate
lowest
admit
within
fi
rst
day
compar
admit
later
cours
hospit
ill
basi
number
studi
reason
benchmark
approxim
icu
cap
patient
mechan
ventil
time
admiss
among
vap
mortal
rate
high
casecontrol
studi
document
mortal
directli
attribut
presenc
pneumonia
antibioticresist
organ
may
add
mortal
rate
vap
increas
virul
rather
organ
often
anticip
present
often
initi
treat
ineffect
antibiot
regimen
hcap
form
np
includ
patient
pneumonia
develop
time
hospit
stay
includ
admiss
expos
drugresist
bacteria
present
health
care
environ
includ
patient
histori
hospit
past
month
admiss
longterm
care
facil
need
dialysi
home
infus
therapi
home
wound
care
antibiot
therapi
past
month
number
studi
defi
ned
risk
factor
sever
form
cap
vap
well
clinic
paramet
associ
increas
risk
patient
mortal
patient
sever
cap
coexist
ill
patient
chronic
ill
increas
likelihood
develop
complic
pneumon
ill
box
common
chronic
ill
patient
respiratori
diseas
chronic
obstruct
lung
diseas
copd
cardiovascular
diseas
diabet
mellitu
addit
certain
habit
cigarett
smoke
alcohol
abus
also
quit
common
sever
cap
cigarett
smoke
identifi
ed
risk
factor
bacterem
pneumococc
infect
common
ill
cap
includ
malign
neurolog
ill
includ
seizur
milder
form
pneumonia
may
sever
present
patient
receiv
antibiot
therapi
prior
hospit
admiss
addit
genet
differ
immun
respons
may
predispos
certain
individu
sever
form
infect
advers
outcom
may
refl
ect
famili
histori
sever
pneumonia
advers
outcom
infect
metaanalysi
patient
cap
overal
mortal
rate
admit
icu
mortal
rate
eleven
prognost
factor
signifi
cantli
associ
differ
odd
ratio
or
mortal
male
sex
pleurit
chest
pain
hypothermia
systol
hypotens
tachypnea
diabet
mellitu
neoplast
diseas
neurolog
diseas
bacteremia
leukopenia
multilobar
infi
ltrate
studi
clinic
featur
predict
poor
outcom
box
includ
advanc
age
older
year
preexist
chronic
ill
type
absenc
fever
admiss
respiratori
rate
greater
breath
per
minut
diastol
systol
hypotens
elev
blood
urea
nitrogen
bun
mgdl
profound
leukopenia
leukocytosi
inadequ
antibiot
therapi
need
mechan
ventil
hypoalbuminemia
presenc
certain
highrisk
organ
type
iii
pneumococcu
aureu
gramneg
bacilli
aspir
organ
postobstruct
pneumonia
studi
found
cap
patient
delay
initi
appropri
antibiot
therapi
hour
mortal
increas
prognost
score
approach
appli
predict
mortal
cap
patient
two
promin
system
pneumonia
sever
index
psi
modifi
cation
british
thorac
societi
rule
refer
psi
complex
score
system
place
patient
one
fi
risk
group
death
basi
age
presenc
male
sex
comorbid
ill
certain
laboratori
physic
fi
nding
tool
good
predict
mortal
heavili
weight
age
comorbid
account
social
need
patient
may
help
defi
ne
optim
site
care
given
patient
approach
assess
presenc
confus
elev
prognost
score
system
use
defi
ne
need
icu
admiss
suggest
icu
care
consid
psi
class
iv
v
score
higher
may
alway
effect
admit
icu
psi
class
iii
risk
death
psi
measur
alway
need
intens
care
convers
patient
higher
psi
class
alway
need
icu
care
fall
highmortalityrisk
group
advanc
age
comorbid
ill
absenc
physiolog
fi
nding
sever
pneumonia
neither
current
prognost
score
system
ideal
defi
ning
need
icu
care
regard
provid
decis
support
inform
must
supplement
clinic
assess
judgment
addit
two
score
approach
view
complementari
one
anoth
exampl
one
recent
studi
compar
psi
good
predict
mortal
identifi
lowmortalityrisk
patient
howev
appear
discrimin
defi
ning
mortal
risk
sever
ill
anoth
studi
ewig
colleagu
examin
criteria
american
thorac
societi
guidelin
defi
ne
sever
cap
found
need
icu
defi
ned
presenc
two
three
minor
criteria
systol
bp
multilobar
diseas
pao
fio
ratio
one
two
major
criteria
need
mechan
ventil
septic
shock
basi
observ
at
guidelin
cap
recommend
sever
cap
could
defi
ned
basi
presenc
featur
investig
shown
use
earli
effect
empir
therapi
improv
surviv
set
sever
cap
retrospect
data
shown
reduc
mortal
admit
cap
patient
treat
within
hour
arriv
hospit
compar
treat
later
ineffect
initi
empir
therapi
potent
predictor
death
associ
mortal
rate
compar
mortal
rate
receiv
initi
effect
therapi
similarli
studi
cap
combin
use
macrolid
antibiot
associ
lower
mortal
therapi
given
among
patient
sever
cap
anoth
import
prognost
fi
nding
clinic
evolut
refl
ect
radiograph
progress
therapi
elderli
cap
often
higher
risk
die
popul
part
advers
prognost
featur
particularli
common
popul
one
seri
mortal
rate
nurs
homeacquir
pneumonia
compar
mortal
rate
patient
cap
one
factor
may
explain
fi
nding
older
patient
often
atyp
clinic
present
pneumonia
may
lead
diagnos
later
advanc
stage
ill
result
increas
risk
death
part
consequ
unusu
clinic
present
patient
come
hospit
evalu
often
delay
establish
correct
diagnosi
lead
delay
initi
time
therapi
increas
risk
die
older
patient
nurs
home
present
pneumonia
includ
separ
categori
hcap
discuss
earlier
mechan
ventil
day
import
risk
factor
np
identifi
ed
risk
includ
older
year
age
malnutrit
serum
albumin
gdl
acut
lung
injuri
acut
respiratori
distress
syndrom
ard
coma
burn
recent
abdomin
thorac
surgeri
multipl
organ
failur
transfus
greater
unit
blood
transport
icu
prior
antibiot
therapi
elev
gastric
ph
antacid
histaminetyp
block
agent
largevolum
aspir
use
nasogastr
tube
rather
tube
place
jejunum
tube
insert
mouth
use
inadequ
endotrach
tube
cuff
pressur
prolong
sedat
paralysi
maintain
patient
supin
posit
bed
use
total
parenter
nutrit
feed
rather
enter
feed
repeat
reintub
patient
mechan
ventil
risk
pneumonia
greatest
fi
rst
day
per
day
declin
thereaft
risk
per
day
day
rate
per
day
lower
noninvas
ventil
respiratori
failur
associ
much
lower
risk
pneumonia
endotrach
intub
relat
pneumonia
ard
particularli
interest
mani
one
third
case
ard
may
result
pneumonia
seri
pneumonia
common
caus
acut
lung
injuri
varieti
cap
serv
caus
ard
secondari
np
common
infect
acquir
patient
establish
ard
howev
shown
patient
ard
develop
pneumonia
gener
late
event
occur
least
day
mechan
ventil
pneumonia
also
present
particular
problem
postop
patient
particularli
elect
thorac
cardiac
abdomin
surgeri
surgic
group
high
risk
pneumonia
includ
victim
major
trauma
particularli
suffer
head
injuri
blunt
chest
trauma
patient
pulmonari
contus
may
diffi
cult
distinguish
process
secondari
lung
infect
basi
clinic
radiograph
fi
nding
factor
associ
greatest
impact
attribut
mortal
accuraci
timeli
initi
antibiot
therapi
use
wrong
therapi
delay
initi
therapi
import
predictor
vap
mortal
initi
appropri
therapi
use
agent
etiolog
pathogen
sensit
reduc
mortal
administr
correct
therapi
later
date
initi
incorrect
therapi
may
effect
reduc
mortal
benefi
accur
empir
therapi
may
appli
patient
may
greatest
infect
p
aeruginosa
aureu
without
sever
degre
multipl
organ
dysfunct
time
therapi
patient
even
use
correct
therapi
reduc
mortal
given
adequ
dose
therapi
reach
site
infect
close
relat
appropri
initi
therapi
abil
decreas
number
andor
spectrum
antimicrobi
therapi
cultur
data
becom
avail
refer
deescal
sever
recent
studi
demonstr
use
deescal
associ
lower
mortal
compar
escal
compar
strategi
make
effort
reduc
antibiot
therapi
choic
administ
specifi
c
agent
also
affect
outcom
one
studi
mrsa
vap
found
mortal
intermitt
infus
vancomycin
twice
high
agent
administ
continu
infus
risk
factor
mortal
includ
prolong
durat
ventil
coma
admiss
creatinin
greater
transfer
anoth
ward
icu
presenc
certain
highrisk
pathogen
particularli
antibioticresist
organ
p
aeruginosa
acinetobact
spp
aureu
bilater
radiograph
abnorm
age
older
year
ultim
fatal
underli
condit
shock
prior
antibiot
therapi
multiplesystem
organ
failur
nonsurg
primari
diagnosi
rise
apach
score
pneumonia
therapi
box
although
number
host
bacteriolog
factor
enhanc
mortal
risk
np
develop
superinfect
oppos
primari
np
particularli
omin
fi
nding
rello
observ
pulmonari
superinfect
mortal
wherea
primari
np
mortal
rate
earlier
studi
graybil
observ
mortal
rate
superinfect
pneumonia
compar
mortal
rate
primari
nosocomi
lung
infect
data
well
inform
fagon
colleagu
trouillet
colleagu
emphas
import
role
prior
antibiot
enhanc
mortal
outcom
like
result
secondari
infect
virul
pathogen
result
antibiot
use
two
pivot
role
prognost
outcom
np
outcom
improv
correct
therapi
chosen
therapi
follow
superinfect
mortal
much
like
gener
infect
involv
diffi
culttotreat
drugresist
organ
pneumonia
result
host
defens
overwhelm
infecti
pathogen
may
occur
patient
inadequ
immun
respons
often
result
underli
comorbid
ill
anatom
abnorm
endobronchi
obstruct
bronchiectasi
therapyinduc
dysfunct
immun
system
corticosteroid
endotrach
intub
addit
genet
variat
immun
respons
make
patient
prone
overwhelm
infect
inadequ
respons
other
prone
acut
lung
injuri
excess
immun
respons
fact
failur
local
immun
respons
respiratori
site
initi
infect
may
explain
patient
develop
acut
lung
injuri
sepsi
infl
ammatori
respons
extend
entir
lung
system
circul
pneumonia
even
occur
patient
adequ
immun
system
host
defens
system
overwhelm
larg
inoculum
bacteria
massiv
aspir
particularli
virul
organ
patient
preexist
immun
patient
inabl
form
adequ
immun
respons
paradigm
mind
easi
understand
previous
healthi
individu
develop
infect
virul
pathogen
virus
infl
uenza
legionella
pneumophila
mycoplasma
pneumonia
chlamydophila
pneumonia
streptococcu
pneumonia
howev
chronic
ill
patient
possibl
infect
virul
organ
also
organ
highli
virul
host
defens
impair
organ
commonli
colon
patient
caus
infect
result
immun
respons
inadequ
organ
includ
enter
gramneg
bacteria
escherichia
coli
klebsiella
pneumonia
p
aeruginosa
acinetobact
spp
fungi
aspergillu
candida
spp
bacteria
enter
lung
via
sever
rout
aspir
previous
colon
oropharynx
common
way
patient
develop
pneumonia
although
pneumonia
result
microaspir
patient
also
aspir
larg
volum
bacteria
impair
neurolog
protect
upper
airway
stroke
seizur
gastrointestin
ill
predispos
vomit
rout
entri
includ
inhal
appli
primarili
virus
legionella
pneumophila
mycobacterium
tuberculosi
hematogen
dissemin
extrapulmonari
site
infect
rightsid
endocard
direct
extens
contigu
site
infect
critic
ill
hospit
patient
bacteria
also
enter
lung
colon
stomach
spread
retrograd
oropharynx
follow
aspir
colon
infect
maxillari
sinu
colon
dental
plaqu
enter
lung
directli
via
endotrach
tube
hand
staff
member
recent
studi
shown
use
nasal
tube
stomach
trachea
predispos
sinus
pneumonia
gastric
sourc
pneumonia
pathogen
ventil
patient
common
endotrach
tube
bypass
fi
ltration
host
defens
function
upper
airway
act
conduit
direct
inocul
bacteria
lung
rout
may
particularli
import
bacteria
colon
insid
endotrach
tube
occur
tracheobronchi
organ
reach
endotrach
tube
site
abl
prolifer
free
impedi
host
defens
system
bacteria
commonli
grow
locat
biofi
lm
promot
growth
multidrugresist
organ
biofi
lm
repres
sequest
nidu
infect
insid
endotrach
tube
particl
dislodg
everi
time
patient
suction
one
mechan
explain
strong
associ
endotrach
intub
pneumonia
given
presenc
biofi
lm
endotrach
tube
may
tempt
regularli
reintub
patient
use
fresh
tube
approach
recommend
reintub
risk
factor
vap
patient
tracheobronchi
fl
ora
spread
endotrach
tube
amplifi
larg
number
similar
phenomenon
occur
respiratori
therapi
equip
ventil
circuit
ventil
circuit
colon
studi
indic
greatest
number
found
site
closest
patient
ventil
suggest
circuit
contamin
origin
patient
one
highli
contamin
site
condens
tube
materi
inadvert
inocul
patient
tube
handl
care
condens
colon
occur
tube
within
hour
appear
frequent
ventil
circuit
chang
use
even
abl
reduc
risk
pneumonia
one
studi
tube
chang
everi
hour
rather
everi
hour
serv
risk
factor
pneumonia
although
patient
ventil
tube
chang
everi
hour
sever
studi
shown
increas
risk
infect
tube
never
chang
chang
infrequ
use
heat
moistur
exchang
may
one
way
avoid
problem
inconsist
effect
prevent
vap
addit
frequent
chang
heat
moistur
exchang
ie
everi
hour
shown
impact
incid
vap
heat
moistur
exchang
chang
frequent
everi
hour
pneumonia
gener
character
symptom
fever
cough
purul
sputum
product
dyspnea
patient
new
progress
lung
infi
ltrate
without
associ
pleural
effus
nonventil
patient
cough
common
fi
nding
cough
present
cap
patient
less
common
elderli
seriou
comorbid
individu
come
nurs
home
patient
cap
intact
immun
system
gener
classic
pneumonia
symptom
elderli
patient
nonrespiratori
present
symptom
confus
fall
failur
thrive
alter
function
capac
deterior
preexist
medic
ill
congest
heart
failur
absenc
clearcut
respiratori
symptom
afebril
statu
predictor
increas
risk
death
pleurit
chest
pain
also
commonli
seen
patient
cap
one
studi
absenc
also
identifi
ed
poor
prognost
fi
nding
certain
clinic
condit
associ
specifi
c
pathogen
patient
cap
associ
evalu
obtain
histori
tabl
exampl
present
subacut
follow
contact
bird
rat
rabbit
possibl
psittacosi
leptospirosi
tularemia
plagu
consid
coxiella
burnetii
q
fever
concern
exposur
parturi
cat
cattl
sheep
goat
francisella
tularensi
rabbit
exposur
hantaviru
exposur
mice
drop
endem
area
c
psittaci
exposur
turkey
infect
bird
legionella
exposur
contamin
water
sourc
sauna
follow
infl
uenza
superinfect
pneumococcu
aureu
includ
mrsa
hemophilu
infl
uenza
consid
travel
endem
area
asia
onset
respiratori
failur
preced
viral
ill
lead
suspicion
viral
pneumonia
could
sever
acut
respiratori
syndrom
sar
avian
infl
uenza
endem
fungi
coccidioidomycosi
histoplasmosi
blastomycosi
occur
welldefi
ned
geograph
area
may
present
acut
symptom
overlap
acut
bacteri
pneumonia
np
patient
often
present
less
defi
nitiv
clinic
fi
nding
particularli
mechan
ventil
clinic
diagnosi
made
patient
new
progress
radiograph
infi
ltrate
along
indic
infect
present
fever
purul
sputum
leukocytosi
recent
clinic
pulmonari
infect
score
cpi
appli
patient
vap
six
criteria
score
scale
pneumonia
diagnos
total
score
least
maximum
criteria
fever
purul
sputum
white
blood
cell
count
oxygen
degre
radiograph
abnorm
presenc
pathogen
sputum
mani
studi
document
vap
diagnos
often
clinic
confi
rmed
microbiolog
diagnosi
obscur
fact
mechan
ventil
patient
colon
enter
gramneg
bacteria
thu
fi
nding
potenti
pathogen
sputum
diagnost
valu
addit
patient
purul
sputum
fever
without
new
infi
ltrate
diagnos
purul
tracheobronch
infecti
complic
mechan
ventil
may
also
requir
antibiot
therapi
pneumonia
take
histori
patient
np
import
identifi
risk
factor
drugresist
organ
ventil
patient
includ
prolong
icu
stay
day
recent
antibiot
therapi
presenc
health
careassoci
pneumonia
cap
patient
risk
factor
drugresist
pneumococcu
includ
recent
therapi
exposur
child
daycar
alcohol
immun
suppress
multipl
medic
comorbid
physic
fi
nding
pneumonia
includ
tachypnea
crackl
rhonchi
sign
consolid
egophoni
bronchial
breath
sound
dull
percuss
patient
also
evalu
sign
pleural
effus
addit
extrapulmonari
fi
nding
sought
rule
metastat
infect
arthriti
endocard
mening
add
suspicion
atyp
pathogen
pneumonia
c
pneumonia
lead
complic
bullou
myring
skin
rash
pericard
hepat
hemolyt
anemia
meningoenceph
one
import
way
recogn
sever
cap
earli
cours
ill
care
count
respiratori
rate
elderli
elev
respiratori
rate
initi
present
sign
pneumonia
preced
clinic
fi
nding
much
day
tachypnea
present
patient
often
elderli
younger
patient
pneumonia
addit
count
respiratori
rate
identifi
patient
sever
ill
commonli
rate
greater
breath
per
minut
even
extens
diagnost
test
etiolog
agent
defi
ned
half
patient
cap
point
limit
valu
diagnost
test
possibl
know
organ
caus
cap
common
caus
cap
pneumococcu
pneumonia
organ
frequent
least
time
resist
penicillin
antibiot
lead
term
drugresist
pneumonia
drsp
fortun
penicillin
resist
unit
state
still
commonli
intermedi
type
penicillin
minimum
inhibitori
concentr
mic
mgl
highlevel
type
penicillin
mic
pneumococc
resist
antibiot
also
common
includ
macrolid
trimethoprimsulfamethoxazol
clinic
relev
impact
outcom
vitro
fi
nding
uncertain
expert
believ
organ
penicillin
mic
greater
mgl
lead
increas
risk
death
patient
sever
cap
consid
risk
drsp
addit
admit
icu
infect
atyp
pathogen
account
infect
either
primari
infect
copathogen
ident
organ
vari
time
geographi
area
legionella
common
caus
sever
cap
wherea
other
chlamydophila
pneumonia
pneumonia
predomin
import
caus
sever
cap
includ
h
infl
uenza
aureu
includ
mrsa
especi
infl
uenza
enter
gramneg
includ
p
aeruginosa
patient
appropri
risk
factor
particularli
bronchiectasi
steroidtr
copd
recent
toxinproduc
strain
mrsa
describ
caus
cap
patient
infl
uenza
viral
infect
communityacquir
mrsa
biolog
genet
distinct
mrsa
caus
np
virul
necrot
associ
product
pantonvalentin
leukocidin
pvl
virus
caus
sever
cap
includ
infl
uenza
viru
well
parainfl
uenza
viru
epidem
virus
coronaviru
caus
sar
avian
infl
uenza
viral
pneumonia
sar
infl
uenza
lead
respiratori
failur
occasion
tuberculosi
endem
fungi
result
sever
pneumonia
unusu
etiolog
consid
especi
patient
epidemiolog
risk
factor
specifi
c
pathogen
discuss
earlier
addit
certain
modifi
factor
may
present
increas
likelihood
cap
caus
certain
pathogen
thu
risk
factor
drsp
includ
therapi
past
month
alcohol
age
older
year
immun
suppress
multipl
medic
comorbid
contact
child
day
care
risk
factor
gramneg
includ
resid
nurs
home
underli
cardiopulmonari
diseas
multipl
medic
comorbid
probabl
aspir
recent
hospit
recent
antibiot
therapi
mani
patient
risk
gramneg
would
reclassifi
ed
health
careassoci
pneumonia
hcap
icu
patient
risk
pseudomon
infect
wherea
other
risk
factor
p
aeruginosa
infect
structur
lung
diseas
bronchiectasi
corticosteroid
therapi
mg
prednisoneday
broadspectrum
antibiot
therapi
day
past
month
previou
hospit
malnutrit
although
aspir
often
consid
risk
factor
anaerob
infect
studi
sever
cap
elderli
patient
aspir
risk
factor
found
popul
like
gramneg
infect
use
sensit
microbiolog
method
anaerob
uncommon
patient
ill
risk
infect
group
bacteria
refer
core
organ
includ
pneumococcu
h
infl
uenza
methicillinsensit
aureu
nonresist
gramneg
e
coli
klebsiella
spp
enterobact
spp
proteu
spp
serratia
marcescen
addit
patient
also
risk
infect
organ
depend
presenc
risk
factor
prolong
hospit
day
prior
antibiot
therapi
recent
hospit
within
day
recent
antibiot
therapi
resid
nurs
home
need
chronic
care
outsid
hospit
patient
risk
factor
possibl
infect
multidrugresist
mdr
gramposit
gramneg
organ
includ
mrsa
p
aeruginosa
acinetobact
spp
recognit
multipl
risk
factor
associ
resist
pathogen
made
clear
patient
earlyonset
np
within
fi
rst
day
hospit
infect
mdr
organ
addit
patient
vap
polymicrobi
infect
involv
multipl
pathogen
data
np
bacteriolog
come
patient
vap
etiolog
nonventil
patient
presum
similar
basi
presenc
risk
factor
drugresist
pathogen
patient
vap
infect
enter
gramneg
common
infect
gramposit
although
frequenc
mrsa
infect
increas
popul
infect
acinetobact
spp
hcap
patient
includ
np
guidelin
group
risk
infect
mdr
gramposit
gramneg
although
icuadmit
patient
ill
infect
organ
one
studi
nurs
home
patient
requir
mechan
ventil
sever
pneumonia
show
organ
present
patient
sever
pneumonia
receiv
antibiot
preced
month
also
good
function
statu
defi
ned
activ
daili
live
approach
bacteriolog
np
import
recogn
hospit
well
icu
within
given
hospit
uniqu
fl
ora
antibiot
suscept
pattern
thu
therapi
need
adapt
organ
given
institut
chang
time
addit
especi
import
know
inform
antibiot
resist
common
factor
contribut
initi
inappropri
empir
antibiot
therapi
choos
wrong
empir
therapi
particular
problem
organ
p
aeruginosa
acinetobact
spp
mrsa
highli
resist
organ
present
patient
develop
vap
least
day
ventil
also
receiv
prior
antibiot
therapi
patient
certain
suspect
pathogen
place
respiratori
isol
protect
staff
patient
infect
organ
includ
primarili
airborn
pathogen
spread
via
aerosol
rout
includ
patient
suspect
tuberculosi
infl
uenza
respiratori
syncyti
viru
epidem
viral
infect
tuberculosi
consid
patient
histori
preced
indol
pneumonia
sever
pneumonia
histori
hiv
infect
recent
immigr
endem
area
infect
patient
mrsa
highli
resist
gramneg
may
need
gown
glove
mask
precaut
avoid
spread
diffi
culttotreat
bacteria
diagnost
test
perform
two
purpos
defi
ne
presenc
pneumonia
identifi
respons
pathogen
form
pneumonia
chest
radiograph
use
identifi
presenc
lung
infi
ltrate
clinic
set
especi
suspect
vap
noninfecti
caus
radiograph
abnorm
chest
radiograph
pattern
gener
use
identifi
etiolog
cap
although
fi
nding
pleural
effus
pneumococcu
h
infl
uenza
pneumonia
pyogen
streptococci
cavit
p
aeruginosa
aureu
anaerob
mrsa
tuberculosi
suggest
certain
group
organ
defi
ning
etiolog
pathogen
patient
cap
often
diffi
cult
half
patient
identifi
ed
etiolog
even
extens
diagnost
test
includ
cultur
blood
sputum
hand
vap
commonli
bacteria
present
sampl
lower
respiratori
tract
secret
presenc
posit
cultur
reliabl
distinguish
infect
colon
patient
cap
chest
radiograph
confi
rm
presenc
pneumonia
use
identifi
complic
sever
ill
patient
fi
nding
multilobar
infi
ltrate
cavit
locul
pleural
effus
suggest
empyema
although
diagnost
test
valuabl
patient
cap
therapi
never
delay
sole
purpos
facilit
test
delay
therapi
associ
increas
mortal
cap
patient
admit
icu
chest
radiograph
blood
lower
respiratori
tract
sputum
endotrach
aspir
bronchoalveolar
lavag
bronchoscop
specimen
cultur
arteri
blood
ga
routin
hematolog
blood
chemistri
test
patient
moderates
pleural
effus
tap
fl
uid
sent
cultur
biochem
analysi
patient
sever
cap
two
set
blood
cultur
like
posit
patient
receiv
antibiot
time
sampl
sign
systol
hypotens
tachycardia
dehydr
elev
white
blood
cell
count
presenc
bacteremia
may
worsen
prognosi
allow
identifi
cation
drugresist
organ
posit
blood
cultur
cap
reveal
pneumococcu
sputum
cultur
accompani
gram
stain
guid
interpret
cultur
result
focu
initi
antibiot
therapi
situat
gram
stain
use
broaden
initi
empir
therapi
enhanc
suspicion
organ
cover
routin
empir
therapi
aureu
suggest
presenc
cluster
gramposit
cocci
especi
time
epidem
infl
uenza
routin
serolog
test
recommend
howev
patient
sever
ill
diagnosi
legionella
pneumophila
made
urinari
antigen
test
test
like
posit
time
admiss
test
specifi
c
serogroup
infect
examin
concentr
urin
pneumococc
antigen
may
also
valuabl
bronchoscopi
indic
routin
diagnost
test
may
necessari
patient
sever
form
cap
establish
etiolog
diagnosi
patient
result
diagnost
test
often
use
focu
initi
broadspectrum
empir
therapi
simpler
regimen
np
diagnos
patient
hospit
least
hour
develop
new
progress
infi
ltrate
chest
radiograph
accompani
least
follow
fever
leukocytosi
purul
sputum
mention
clinic
fi
nding
may
sensit
specifi
c
infect
effort
improv
clinic
diagnosi
pneumonia
involv
previous
mention
cpi
mani
patient
suspect
np
diagnos
suggest
rapid
clinic
respons
natur
clinic
fi
nding
diagnos
includ
atelectasi
congest
heart
failur
rapid
clinic
resolut
case
lack
respons
therapi
infl
ammatori
lung
diseas
extrapulmonari
infect
sinus
central
line
infect
intraabdomin
infect
presenc
unusu
drugresist
pathogen
addit
presenc
pathogen
organ
sputum
cultur
diagnost
fi
nding
separ
oropharyng
tracheobronchi
colon
parenchym
lung
infect
situat
complic
ventil
patient
nosocomi
infecti
tracheobronch
ill
clinic
featur
pneumonia
new
lung
infi
ltrate
ill
may
also
requir
antibiot
therapi
involv
pathogen
vap
effort
make
diagnosi
secur
avoid
overus
antibiot
investig
use
quantit
sampl
lower
respiratori
secret
collect
either
bronchoscop
bronchoalveolar
lavag
protect
specimen
brush
nonbronchoscop
endotrach
aspir
nonbronchoscop
cathet
lavag
particularli
patient
suspect
vap
quantit
cultur
collect
investig
defi
ned
presenc
pneumonia
growth
bacteria
concentr
predefi
ned
threshold
concentr
although
result
guid
therapi
decis
clinician
use
antibiot
therapi
regardless
quantit
cultur
data
patient
clinic
sign
sepsi
suspect
pneumonia
regardless
whether
quantit
cultur
use
patient
suspect
np
lower
respiratori
tract
cultur
collect
prior
start
antibiot
therapi
quantit
cultur
sputum
tracheal
aspir
obtain
fi
nding
report
semiquantit
light
moder
heavi
growth
bacteria
unfortun
neg
cultur
diffi
cult
interpret
patient
initi
chang
antibiot
therapi
preced
hour
howev
either
quantit
semiquantit
cultur
neg
show
highli
resist
pathogen
antibiot
chang
past
hour
therapi
often
stop
focus
narrow
spectrum
therapi
patient
sever
pneumonia
algorithm
initi
empir
therapi
develop
basi
like
etiolog
pathogen
given
patient
clinic
set
diagnost
test
reveal
specifi
c
etiolog
pathogen
therapi
focus
result
addit
mention
earlier
anticip
pathogen
present
diagnost
sampl
may
possibl
stop
empir
coverag
organ
fig
recent
combin
empir
antibiot
therapi
sever
pneumonia
univers
given
physician
work
icu
rational
approach
provid
broad
antimicrobi
coverag
prevent
emerg
resist
therapi
potenti
provid
synergist
activ
antibiot
combin
aminoglycosid
p
aeruginosa
pneumonia
howev
bacterem
p
aeruginosa
pneumonia
combin
therapi
gener
aminoglycosid
shown
superior
monotherapi
one
practic
problem
approach
aminoglycosid
class
antibiot
narrow
therapeutictotox
ratio
high
incid
nephrotox
particularli
elderli
patient
drug
use
import
use
enough
antibiot
achiev
high
peak
serum
level
optim
effi
caci
also
avoid
elev
trough
level
correl
toxic
peak
serum
level
monitor
level
gentamicin
tobramycin
amikacin
associ
favor
outcom
one
limit
aminoglycosid
rel
poor
penetr
bronchial
secret
achiev
serum
concentr
site
addit
antimicrobi
activ
reduc
low
ph
level
common
bronchial
secret
patient
pneumonia
concern
may
explain
fi
nding
one
studi
addit
aminoglycosid
imipenem
ad
effi
caci
sever
np
ad
renal
toxic
addit
metaanalysi
valu
ad
aminoglycosid
critic
ill
patient
includ
mani
pneumonia
found
therapeut
benefi
becom
standard
administ
aminoglycosid
combin
total
dose
singl
dose
rather
divid
dose
approach
theoret
possibl
prolong
postantibiot
effect
aminoglycosid
hope
oncedaili
dose
improv
effi
caci
reduc
least
increas
toxic
reduc
need
monitor
serum
level
one
metaanalysi
approach
prove
littl
advantag
regard
effi
caci
safeti
despit
fi
nding
aminoglycosid
use
oncedaili
dose
recommend
simpler
requir
less
intens
monitor
measur
trough
level
recent
develop
newer
cephalosporin
carbapenem
quinolon
high
potenc
broad
antibacteri
activ
well
resist
degrad
bacteri
permit
introduct
monotherapi
even
patient
sever
np
provid
certain
highrisk
organ
absent
p
aeruginosa
acinetobact
spp
mrsa
absenc
highli
resist
pathogen
antibiot
effect
monotherapi
sever
vap
includ
imipenem
meropenem
cefepim
ciprofl
oxacin
highdos
levofl
oxacin
mg
daili
piperacillintazobactam
patient
sever
pneumonia
usual
necessari
start
algorithm
approach
manag
sever
pneumonia
patient
categor
communityacquir
pneumonia
nosocomi
pneumoniaventilatorassoci
pneumonia
group
undergo
diagnost
test
follow
empir
therapi
base
like
etiolog
pathogen
result
clinic
respons
use
guid
durat
therapi
decid
whether
broaden
differenti
diagnosi
process
camrsa
communityacquir
mrsa
cap
communityacquir
pneumonia
mdr
multidrug
resist
np
nosocomi
pneumonia
vap
ventilatorassoci
pneumonia
therapi
multipl
agent
tracheal
aspir
lower
respiratori
tract
cultur
becom
avail
usual
possibl
deescal
monotherapi
particularli
highli
resist
organ
absent
circumst
monotherapi
use
patient
sever
cap
effi
caci
approach
demonstr
suspect
bacterem
infect
p
aeruginosa
empir
therapi
vap
patient
risk
factor
infect
mdr
pathogen
patient
np
aureu
p
aeruginosa
identifi
ed
cultur
etiolog
pathogen
monotherapi
never
attempt
thirdgener
cephalosporin
possibl
emerg
resist
therapi
result
product
chromosom
enterobacteriacea
group
organ
p
aeruginosa
target
organ
therapi
antibiot
effi
caci
pathogen
necessari
antipseudomon
antibiot
includ
penicillin
piperacillin
azlocillin
mezlocillin
ticarcillin
carbenicillin
thirdgener
cephalosporin
ceftazidim
cefoperazon
fourthgener
cephalosporin
cefepim
carbapenem
imipenem
meropenem
monobactam
aztreonam
use
penicillinallerg
patient
inhibitor
combin
ticarcillinclavulan
piperacillintazobactam
antipseudomon
agent
includ
quinolon
ciprofl
oxacin
highdos
levofl
oxacin
aminoglycosid
amikacin
gentamicin
tobramycin
icuadmit
cap
initi
therapi
direct
drsp
legionella
atyp
pathogen
enter
gramneg
select
organ
basi
epidemiolog
risk
assess
therapi
chosen
depend
whether
patient
risk
p
aeruginosa
modifi
risk
factor
list
earlier
treatment
algorithm
icuadmit
cap
patient
receiv
empir
monotherapi
even
one
new
quinolon
recommend
base
fact
effi
caci
especi
mening
complic
pneumonia
effect
dose
safeti
quinolon
monotherapi
establish
icuadmit
cap
patient
one
recent
studi
compar
levofl
oxacin
combin
singleag
regimen
shown
effect
patient
septic
shock
treat
mechan
ventil
recommend
therapi
sever
cap
absenc
pseudomon
risk
factor
select
intraven
eg
cefotaxim
ceftriaxon
ertapenem
inhibitor
combin
combin
either
intraven
macrolid
intraven
antipneumococc
quinolon
levofl
oxacin
moxifl
oxacin
patient
pseudomon
risk
factor
therapi
twodrug
regimen
use
antipseudomon
imipenem
meropenem
piperacillintazobactam
cefepim
plu
ciprofl
oxacin
activ
antipseudomon
quinolon
levofl
oxacin
mg
daili
altern
threedrug
regimen
use
antipseudomon
plu
aminoglycosid
plu
either
intraven
antipneumococc
quinolon
levofl
oxacin
moxifl
oxacin
macrolid
addit
antibiot
approach
therapi
outlin
earlier
sever
consider
manag
cap
includ
provid
fi
rst
dose
therapi
soon
possibl
within
hour
arriv
hospit
provid
coverag
patient
atyp
pathogen
use
either
macrolid
quinolon
regimen
basi
data
approach
reduc
mortal
even
patient
pneumococc
bacteremia
use
combin
therapi
gener
addit
atyp
pathogen
coverag
pneumococc
coverag
associ
reduc
mortal
compar
monotherapi
addit
certain
adjunct
therapi
consid
includ
oxygen
chest
physiotherapi
least
ml
sputum
daili
poor
cough
respons
aerosol
bronchodil
corticosteroid
hypotens
possibl
rel
adren
insuffi
cienci
present
analysi
use
activ
protein
c
patient
septic
shock
demonstr
patient
pivot
clinic
trial
underli
cap
activ
protein
c
effect
cap
patient
apach
ii
score
greater
psi
class
iv
v
score
least
patient
pneumococc
infect
inadequ
therapi
also
benefi
ted
although
benefi
minim
treat
adequ
therapi
addit
valu
patient
rel
adren
insuffi
cienci
corticosteroid
may
help
sever
cap
immunomodul
effect
one
random
control
trial
patient
compar
hydrocortison
infus
mgday
placebo
found
steroid
therapi
reduc
mortal
length
stay
durat
mechan
ventil
fi
nding
requir
studi
confi
rm
benefi
adjunct
therapi
inform
proper
durat
therapi
patient
cap
especi
sever
ill
scarc
even
presenc
pneumococc
bacteremia
short
durat
therapi
may
possibl
rapid
switch
intraven
oral
therapi
respond
patient
gener
pneumonia
treat
day
patient
respond
rapidli
receiv
accur
empir
therapi
correct
dose
presenc
extrapulmonari
infect
mening
identifi
cation
certain
pathogen
eg
bacterem
aureu
p
aeruginosa
may
requir
longer
durat
therapi
identifi
cation
l
pneumophila
pneumonia
may
requir
least
day
therapi
depend
sever
ill
host
defens
impair
although
recent
data
shown
quinolon
therapi
may
best
approach
manag
durat
short
day
levofl
oxacin
mg
may
effect
switch
oral
therapi
even
sever
ill
patient
may
facilit
use
quinolon
highli
bioavail
achiev
serum
level
oral
therapi
intraven
therapi
current
controversi
need
empir
therapi
direct
communityacquir
mrsa
expert
recommend
organ
target
patient
sever
necrot
cap
follow
viral
ill
particularli
infl
uenza
optim
therapi
defi
ned
vancomycin
alon
may
suffi
cient
led
clinic
failur
presum
activ
pvl
toxin
accompani
communityacquir
mrsa
reason
may
necessari
add
clindamycin
vancomycin
use
linezolid
latter
agent
inhibit
toxin
product
antibiot
therapi
given
promptli
fi
rst
clinic
suspicion
pneumonia
empir
therapi
dictat
consid
whether
patient
risk
infect
mdr
pathogen
primarili
presenc
recent
antibiot
therapi
prolong
hospit
stay
develop
infect
resid
nurs
home
chronic
care
set
dialysi
center
risk
factor
hcap
patient
without
risk
mdr
pathogen
treat
core
pathogen
list
earlier
gener
monotherapi
regimen
secondgener
nonpseudomon
thirdgener
cephalosporin
inhibitor
combin
ertapenem
quinolon
levofl
oxacin
moxifl
oxacin
patient
allerg
penicillin
therapi
quinolon
combin
clindamycin
aztreonam
probabl
hcap
patient
need
therapi
direct
mdr
pathogen
monotherapi
success
absenc
mdr
pathogen
mdr
pathogen
like
hcap
patient
least
two
follow
sever
infect
recent
antibiot
therapi
past
month
poor
function
statu
select
empir
therapi
regimen
necessari
know
antibiot
patient
recent
receiv
within
past
day
choos
agent
differ
class
repeat
use
class
antibiot
may
drive
resist
class
especi
pathogen
p
aeruginosa
similar
fi
nding
made
patient
bacterem
pneumococc
pneumonia
cap
repeat
use
agent
within
month
may
mean
patient
treat
agent
pneumococcu
like
resist
addit
recent
use
quinolon
may
present
particular
problem
icu
recent
quinolon
therapi
may
predispos
quinoloneresist
organ
also
infect
mdr
pathogen
extendedspectrum
produc
gramneg
mrsa
patient
vap
import
use
correct
dose
antibiot
see
box
recommend
dose
patient
normal
renal
function
although
possibl
identifi
basi
risk
factor
patient
like
infect
mdr
pathogen
import
realiz
hospit
icu
uniqu
organ
pattern
antimicrobi
resist
pattern
chang
time
therefor
necessari
monitor
local
pattern
resist
choos
empir
therapi
like
effect
given
clinic
set
one
concept
incorpor
studi
empir
therapi
antibiot
rotat
mean
standard
empir
regimen
intent
vari
time
expos
bacteria
differ
antibiot
thu
minim
select
pressur
resist
studi
approach
effect
reduc
incid
infect
resist
organ
one
limit
antibiot
rotat
may
mean
use
regimen
repeatedli
patient
may
risk
factor
select
resist
addit
unansw
question
long
cycl
therapi
last
agent
cycl
effect
approach
medic
versu
surgic
patient
whether
cycl
focu
gramposit
gramneg
organ
patient
risk
mdr
pathogen
gener
requir
combin
therapi
rather
monotherapi
combin
therapi
valuabl
provid
broadspectrum
coverag
therebi
minim
chanc
initi
inappropri
therapi
recent
data
shown
combin
therapi
use
aminoglycosid
effect
monotherapi
sever
infect
includ
caus
p
aeruginosa
dualpseudomon
therapi
still
recommend
patient
risk
pathogen
order
minim
chanc
initi
ineffect
therapi
empir
therapi
patient
risk
mdr
pathogen
includ
aminoglycosid
quinolon
ciprofl
oxacin
highdos
levofl
oxacin
plu
antipseudomon
imipenem
meropenem
piperacillintazobactam
aztreonam
cefepim
patient
risk
second
icuacquir
infect
may
prudent
use
aminoglycosid
fi
rst
episod
infect
reserv
quinolon
box
ciprofl
oxacin
mg
everi
hour
levofl
oxacin
mg
everi
day
imipenem
gm
everi
hour
mg
everi
hour
meropenem
gm
everi
hour
piperacillintazobactam
gm
everi
hour
cefepim
gm
everi
hour
ceftazidim
gm
everi
hour
gentamicin
tobramycin
mgkgd
amikacin
mgkgd
linezolid
mg
everi
hour
vancomycin
mgkg
everi
hour
subsequ
infect
concern
quinolon
induct
mdr
could
limit
subsequ
therapi
option
patient
suspect
mrsa
tracheal
aspir
gram
stain
show
gramposit
organ
risk
factor
third
drug
ad
could
either
linezolid
vancomycin
recent
data
suggest
superior
linezolid
surviv
clinic
cure
patient
document
mrsa
vap
mani
patient
np
get
initi
empir
therapi
broadspectrum
thu
import
consid
deescal
initi
regimen
serial
clinic
microbiolog
data
becom
avail
see
fig
patient
receiv
broadspectrum
regimen
cultur
show
mdr
organ
patient
fi
nish
therapi
six
monotherapi
regimen
document
effect
sever
vap
absenc
mdr
organ
ciprofl
oxacin
imipenem
meropenem
piperacillintazobactam
cefepim
highdos
levofl
oxacin
p
aeruginosa
present
combin
therapi
aminoglycosid
continu
day
patient
switch
monotherapi
agent
organ
sensit
deescal
use
mean
either
switch
narrow
spectrum
regimen
use
fewer
drug
mortal
vap
reduc
compar
patient
deescal
mani
unreal
opportun
exist
use
approach
patient
p
aeruginosa
infect
sensit
pathogen
good
clinic
respons
neg
respiratori
tract
cultur
lower
respiratori
tract
cultur
neg
may
possibl
stop
therapi
especi
altern
diagnosi
suspect
shorten
durat
therapi
addit
cultur
show
initi
empir
regimen
appropri
patient
good
clinic
respons
refl
ect
drop
cpi
may
possibl
reduc
durat
therapi
littl
day
although
may
possibl
etiolog
pathogen
p
aeruginosa
mrsa
adjunct
therapeut
measur
necessari
patient
includ
chest
physiotherapi
aerosol
bronchodil
mucolyt
agent
select
patient
infect
highli
resist
organ
respond
system
antibiot
may
valuabl
add
aerosol
antibiot
eg
gentamicin
tobramycin
colistin
ceftazidim
aerosol
administr
antibiot
offer
advantag
achiev
high
concentr
antibiot
site
infect
result
may
possibl
overcom
problem
poor
lung
penetr
certain
agent
aminoglycosid
provid
high
level
antibiot
necessari
kill
certain
resist
organ
local
administ
antibiot
rare
absorb
system
toxic
minim
despit
theoret
advantag
mani
effi
caci
question
remain
answer
clinic
trial
pend
inform
local
instil
aerosol
antibiot
usual
recommend
routin
treatment
pneumonia
may
role
adjunct
therapi
patient
mdr
organ
respond
system
therapi
pneumonia
clinic
syndrom
patient
diagnosi
actual
lung
infect
may
infect
unusu
nonsuspect
pathogen
addit
patient
develop
complic
ill
therapi
situat
may
lead
appar
nonrespons
therapi
effect
therapi
patient
cap
becom
afebril
day
clinic
respons
day
similarli
even
vap
patient
improv
particularli
oxygen
day
nonrespond
patient
either
cap
vap
evalu
altern
diagnos
infl
ammatori
lung
diseas
atelectasi
heart
failur
malign
pulmonari
hemorrhag
pulmonari
embolu
nonpneumon
infect
resist
unusu
pathogen
includ
tuberculosi
fungal
infect
pneumonia
complic
empyema
lung
abscess
drug
fever
antibioticinduc
coliti
secondari
site
infect
central
line
infect
intraabdomin
infect
box
evalu
nonrespond
patient
individu
may
includ
ct
scan
prevent
cap
import
group
patient
especi
elderli
patient
risk
higher
frequenc
infect
sever
cours
ill
appropri
patient
vaccin
pneumococc
infl
uenza
vaccin
cigarett
smoke
stop
atrisk
patient
even
patient
recov
cap
immun
hospit
appropri
prevent
futur
episod
infect
evalu
patient
vaccin
need
provis
inform
smoke
cessat
perform
standard
use
evalu
hospit
care
cap
patient
uncertainti
whether
patient
recent
vaccin
probabl
best
give
pneumococc
vaccin
repeat
administr
even
often
recommend
gener
associ
advers
reaction
hospitalbas
immun
recommend
one
studi
found
among
patient
pneumonia
treat
hospit
hospit
preced
year
addit
patient
highrisk
condit
would
qualifi
ed
receiv
pneumococc
vaccin
basi
observ
seem
like
mani
case
cap
could
prevent
pneumococc
vaccin
given
hospit
patient
qualifi
vaccin
regardless
hospit
although
singl
method
reliabl
prevent
np
multipl
small
intervent
may
benefi
especi
focus
modifi
abl
risk
factor
infect
recent
intervent
combin
ventil
bundl
demonstr
reduc
incid
vap
appli
care
bundl
includ
multipl
intervent
diffi
cult
know
individu
manipul
valuabl
success
bundl
includ
intervent
elev
head
bed
degre
avoid
risk
aspir
present
supin
posit
daili
interrupt
sedat
attempt
wean
peptic
ulcer
diseas
prophylaxi
endotrach
tube
suction
possibl
close
suction
system
hand
wash
care
oral
care
tight
control
blood
glucos
despit
success
approach
one
recent
random
studi
demonstr
lack
benefi
feasibl
routin
headoftheb
elev
wide
use
measur
mechan
ventil
patient
avoid
larg
inocula
bacteria
lung
care
handl
ventil
circuit
tube
mobil
respiratori
secret
frequent
suction
use
rotat
bed
therapi
select
individu
nutrit
support
enter
prefer
parenter
place
feed
tube
small
bowel
avoid
aspir
like
stomach
tube
avoid
larg
gastric
residu
give
enter
feed
addit
tube
insert
stomach
trachea
insert
mouth
nose
whenev
possibl
avoid
obstruct
nasal
sinus
prevent
nosocomi
sinus
lead
np
special
adapt
endotrach
tube
allow
continu
aspir
subglott
secret
may
interrupt
oropharyng
tracheal
transfer
bacteria
reduc
incid
pneumonia
endotrach
intub
risk
pneumonia
noninvas
posit
pressur
ventil
use
whenev
possibl
approach
associ
lower
pneumonia
risk
tradit
mechan
ventil
prophylact
system
topic
antibiot
specifi
c
role
data
suggest
patient
coma
caus
stroke
head
trauma
may
aspir
emerg
intub
may
benefi
cours
system
antibiot
select
digest
decontamin
includ
system
topic
intestin
antibiot
remain
controversi
method
reduc
incid
pneumonia
literatur
support
exist
select
popul
approach
carri
risk
promot
antibiot
resist
np
hospitalacquir
infect
like
lead
death
patient
typic
crude
mortal
rate
infect
even
higher
rate
seen
patient
mechan
ventil
patient
die
np
one
third
one
half
death
direct
result
infect
term
attribut
mortal
good
simpl
predictor
poor
outcom
cap
presenc
least
indic
confus
admiss
blood
urea
nitrogen
greater
mgdl
low
blood
pressur
systol
blood
pressur
mm
hg
diastol
blood
pressur
lower
mm
hg
respiratori
rate
higher
breath
per
minut
age
least
import
risk
factor
mortal
patient
vap
inappropri
antibiot
therapi
risk
factor
mortal
includ
respiratori
failur
coma
admiss
bilater
radiograph
abnorm
infect
resist
organ
number
common
therapeut
intervent
increas
risk
hospitalacquir
pneumonia
chosen
care
includ
endotrach
intub
corticosteroid
antibiot
immunosuppress
total
parenter
nutrit
certain
strategi
feed
enter
provid
prophylaxi
intestin
bleed
common
pathogen
cap
pneumococcu
legionella
pneumophila
atyp
pathogen
major
concern
patient
sever
cap
enter
gramneg
bacteria
common
pathogen
caus
np
mdr
pathogen
includ
gramneg
staphylococcu
aureu
includ
mrsa
also
occur
particularli
patient
hospit
least
day
receiv
antibiot
therapi
onset
pneumonia
np
often
treat
make
clinic
diagnosi
clinic
approach
overli
sensit
patient
satisfi
clinic
defi
nition
pneumonia
diseas
process
invas
diagnost
method
use
quantifi
bacteriolog
np
patient
may
alway
identifi
patient
pneumonia
particularli
presenc
prior
antibiot
therapi
methodolog
question
make
tool
controversi
patient
manag
uncertain
favor
alter
patient
outcom
icu
uniqu
bacteriolog
inform
consid
choos
empir
therapi
np
choos
antibiot
patient
sever
pneumonia
take
histori
recent
antibiot
use
avoid
use
agent
prescrib
past
month
patient
cap
agent
prescrib
past
week
patient
vap
although
initi
empir
antibiot
therapi
sever
pneumonia
necessarili
broadspectrum
effort
made
reevalu
clinic
respons
microbiolog
data
narrow
spectrum
therapi
number
drug
usual
done
day
patient
good
clinic
respons
durat
therapi
reduc
day
patient
improv
day
therapi
necessari
determin
anoth
diseas
process
pneumonia
infect
caus
drugresist
unsuspect
pathogen
treat
patient
sever
pneumonia
import
use
correct
dose
correct
antibiot
use
low
dose
factor
lead
poor
outcom
cap
prevent
use
vaccin
particularli
hospitalbas
program
wide
use
strategi
np
prevent
use
ventil
bundl
may
valuabl
care
appli
impact
individu
compon
unknown
